Objective decision making between conventional and oncoplastic breast-conserving surgery or mastectomy: An aesthetic and functional prospective cohort study.
Introduction
Breast cancer is the most common malignant disease in women, with a gradually increasing incidence, while mortality is decreasing nowadays. The Hungarian National
Cancer Registry recorded nearly 7,900 new cases of breast cancer in women, with more than 2,100 deaths in 2014.
The improved understanding of tumour biology in the 1980s and 1990s brought a paradigm shift: ultra-radical breast surgeries were abandoned, and breast cancer began to be considered a systematic disease, based on multidisciplinary and scientific evidence (so-called evidence-based medicine). Breast-conserving surgery (BCS) and adjuvant whole-breast radiotherapy (WBRT) have become the gold standard for the vast majority of patients with early-stage breast cancer. As a result of population screening programmes and developments in diagnostics, breast cancer is increasingly diagnosed at an early stage (ST. 0-II.), which facilitates the possibility of organ-preservation; currently with an average rate of 70%.
Generally, fair to poor cosmetic outcomes following conservative BCS and WBRT are observed in as many as one-third of treated cases resulting in decreased quality of life for the patients. It is well known that good aesthetics have been associated with better psychological recovery and improved quality of life, which has become more important as the improvements in treatments of breast cancer have led to longer survival of the breast cancer patients. The main factor influencing breast deformities following conventional BCS is the large volume of the resected specimen relative to the total breast volume producing asymmetry, retraction, and volume changes in the breast as well as fibrosis of the open cavity during healing. The location of the excision in the different breast quadrants further increases the correlation between the resected volume and a poor cosmetic outcome. There is no consensus in the current literature regarding the maximum removable volume; however, a breast volume loss of over 20% generally leads to significant defects of the breast, although lower percentage volumes have been reported to do so as well.
A sophisticated, organ-preserving breast surgery has developed in the last decade to eliminate the disadvantages of the significant excision in relation to the volume of the breast, and those of the conventional BCSes mentioned earlier, that was named Werner Audretsch oncoplastic breast surgery (OPS). The base of the OPS is that it fills the cavity left after the radical elimination of the tumor by mobilizing and transpositioning the surrounding gland 4 pillars (volume displacement) or using local, neighbouring or distant flaps (volume replacement). OPS includes the simultaneous correction of the defects of partial mastectomy based on the principles of reconstructive plastic surgery, contralateral breast symmetrization surgeries and immediate breast reconstruction (IBR) after mastectomy in wider sense.
Presently, nearly 70% of breast cancer cases are eligible for BCS; however, the number of BCS procedures has slightly declined over the last decade. Up to 30% of women may present residual deformity requiring surgical correction after breast-conserving therapy (BCT), and a number of women may need mastectomy after initial BCT because incomplete resection margins or local recurrence (LR), not to mention the expensive preoperative marking techniques of the non-palpable tumors, the intraoperative histological or radiological examinations of the specimen and logistically complicated absolute indication for adjuvant WBRT. The above-detailed OPS techniques allow maximal radicality in BCS resulting in acceptable or excellent cosmetic outcomes mainly in patients with moderate-or large-sized breasts.
However, according to the current literature, 30-40% of patients still undergo mastectomy due to one or more of the following: unfavourable tumour location, unfavourable breast-to-tumour volume ratio in patients with small-to-intermediate sized breasts, multifocal disease, extensive ductal carcinoma in situ, inability to reach free margins, rejection of radiotherapy (RT), and patient preference (e.g., based on whether they carry the BRCA1/2 gene mutation). Nowadays beyond the oncological reasons, the patients as well as the surgeons opt for mastectomy more easily, even in cases of unfavourable location of the tumor, breast-to-tumor volume ratio or genetic disorders. An increasing rate of IBR can be noticed nationwide in last two decades. The fact that IBR performed during therapeutic or prophylactic postmastectomy (in cases of appropriate patient selection) has become an oncologically accepted procedure and the most important tool of rehabilitation, providing excellent aesthetic outcome and quality of life, avoiding the feared cosmetic drawbacks of mastectomy. In the US, the percentage of mastectomies combined with IBR increased from 12.9% in 2000 to 36.3% in 2009, demonstrating the significance of IBR.
Nowadays the implant-based breast reconstruction (BR) is the most frequent technique following mastectomy in breast cancer and/or BRCA 1/2 mutation carriers. The so-called, 
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In total, 350 patients were enrolled in this study. One hundred fifty patients were excluded due to histological requirements for re-excision, mastectomy and/or axillary lymph node dissection (ALND) (n=61), histological results not indicating RT (n=15), more than 5% body weight loss or gain (n=67), or voluntarily patient withdrawal (n=7). After the homogenization of the investigated population, the remaining 200 patients were statistically analyzed. The average age was 56 years, and the mean breast volume was 625.22 cm³. The average percentage of breast volume excised was 14.73%, and the average weight of the excised specimens was 85.58 g. Regarding the breast cancer staging characteristics of the patients, 15 women were pTispN0(sn), 132 were pT1a-cpN0(sn), 44 were pT2pN0(sn), 3
were pT0-1pN1mi(sn), 5 were pT3pN0(sn), and 1 was pT2pN3c. The mean pathological upper-inner quadrant, and 9-10% in the lower-inner quadrant. In cases involving a predictably larger volume loss than discussed above and in patients with medium or large breasts, oncoplastic BCS might be a better treatment choice than conventional BCS, whereas patients with small breasts might benefit from mastectomy and reconstruction.
The calculated cut-off values for each breast quadrant contribute more objective information to the literature, which may aid the preoperative decision-making process. depending on its size and thickness. The present retrospective cohort study showed that DTI BR using ULTRAPRO ® mesh can provide good aesthetics, a satisfactory quality of life and acceptable emotional/social functioning and body image. The overall complication rate was 18.3%, with a rate of surgical intervention of 11.4%. The most common complication was seroma formation (5.1%), while infection (4.5%) was found to be the second most common complication. It should be noted that complications occurred in 50% of the breast surgery cases in which previous RT was performed with pre-existing scars on the breast. This rate was seven-fold higher than in cases without these factors. The data from the present retrospective cohort study demonstrate that the use of ULTRAPRO ® mesh in DTI BR can be safe, feasible, and a low-cost procedure with encouraging aesthetic results. According to our findings and statistical analysis, there were no significant correlations between active smoking, BMI, diabetic co-morbidity, cup size or type of incision and the observed complications, however the study concluded that a history of BCT added a potential risk to DTI BR using ULTRAPRO ® mesh. According to this and recent reports of increased risk in patients with active smoking, BMI >25, co-morbidities (i.e., diabetes), and large-sized breasts (although this was not verified in the present study), patient selection should be considered prior to DTI BR. 
Assessing the
